RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals
The firm said that oncology and immunology would remain critical areas of focus for deal-making, as 20 out of 34 recent deals, including Pfizer's $43B acquisition of cancer drugmaker Seagen.
https://www.msn.com/en-us/money/companies/morgan-stanley-sees-180b-patent-cliff-380b-deal-capacity-fueling-biopharma-m-a/ar-BB1pVzpK?item=flightsprg-tipsubsc-v1a?loadin=defaultbrowser